A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study

NCT03936192 | Withdrawn Phase 3 DMC

• 1 other identifier: EF 156
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, and active-drug, 12-week, multicenter clinical study. Participants will be randomized 2: 2: 1 to receive the combination of glucosamine sulfate + meloxicam (experimental group), combination of glucosamine sulfate + chondroitin sulfate (active control group) or placebo.

Conditions

Knee Osteoarthritis

Outcome Measures

Primary Outcomes (1)

• To assess whether the efficacy of glucosamine + meloxicam sulfate treatment is superior to the efficacy of treatment with glucosamine sulfate + chondroitin sulfate in improving pain in subjects with symptomatic primary knee OA treated for 4 weeks.

  Absolute variation of the "pain" subscale score of the WOMAC questionnaire (0 to 100mm) 4 weeks (V2) after starting treatment in relation to the basal score (VR);

  4 weeks

Study Arms (3)

glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)

EXPERIMENTAL

glucosamine sulfate 1500mg plus meloxicam 15mg combination, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.

Drug: glucosamine sulphate 1500mg and meloxicam 15mg

Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg

ACTIVE COMPARATOR

Glucosamine sulfate 1500mg plus Chondroitin Sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.

Drug: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg

Placebo

PLACEBO COMPARATOR

Placebo administered once daily for 12 weeks

Drug: Placebos

Interventions

glucosamine sulphate 1500mg and meloxicam 15mg DRUG

glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.

Also known as: glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)

glucosamine sulfate 1500mg and meloxicam 15mg (Eurofarma)

Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg DRUG

Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)

Also known as: glucosamine sulfate 1500mg and chondroitin sulfate 1200mg (Eurofarma)

Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg

Placebos DRUG

Placebo administered once daily for 12 weeks.

Placebo

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age of 40 to 75 years (both inclusive).
• Clinical and radiological diagnosis of primary (idiopathic) knee osteoarthritis according to the American College of Rheumatology (ACR) criteria.
• Radiological classification of Kellgren and Lawrence of grades 2 or 3 on X-ray of the target knee.
• Presence of painful symptoms in the target knee in the last 3 months due to osteoarthritis.
• Visual analogue scale for evaluation of knee osteoarthritis pain by the research participant ≥ 40 mm at the screening visit.
• Mean score ≥ 40mm on the "pain" subscale (0 to 100mm) on the target knee of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire at the randomization visit.
• ACR functional class from I to III.
• Signature of the Informed Consent Form before performing any study procedure.

You may not qualify if:

• Diagnosis of septic arthritis, inflammatory arthritis (such as rheumatoid arthritis), gout, pseudogout, Paget's disease, dysplasias or congenital articular anomalies.
• Severe joint misalignment in the target knee, defined by the researcher.
• History of severe trauma or surgery (including arthroscopy) in the target knee within 6 months prior to the study selection visit.
• Symptomatic osteoarthritis of the ipsilateral hip.
• Use of non-steroidal anti-inflammatory, dipyrone, opioid or narcotic analgesics, collagen and herbal remedies for osteoarthritis from the screening visit, or a washout period for such drugs less than those defined by the protocol, prior to the visit randomization. The use of antidepressants and pain modulating medicinal products should not be started from the screening visit, but they should be kept stable during the study if they are already being used prior to the screening visit.
• Oral, intravenous or intramuscular corticosteroid therapy within 30 days prior to study visit visit.
• Intra-articular injection of corticosteroids, hyaluronic acid and / or platelet-rich plasma at the target knee within 6 months prior to the study selection visit.

Sponsors & Collaborators

• Eurofarma Laboratorios S.A.: lead

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Glucosamine; Meloxicam; Chondroitin Sulfates

Condition Hierarchy (Ancestors)

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Intervention Hierarchy (Ancestors)

Hexosamines; Amino Sugars; Carbohydrates; Thiazines; Sulfur Compounds; Organic Chemicals; Thiazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Chondroitin; Glycosaminoglycans; Polysaccharides

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Participant and Investigator
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: glucosamine sulphate 1500mg + meloxicam 15mg, produced by Eurofarma Laboratories S.A., administered once a day for 12 weeks. Glucosamine sulfate 1500mg + Chondroitin sulfate 1200mg, produced by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks. Placebo administered once daily for 12 weeks.

Study Record Dates

• First Submitted: April 29, 2019
• First Posted: May 3, 2019
• Study Start: January 1, 2019
• Primary Completion: February 1, 2021
• Study Completion: February 1, 2021
• Last Updated: April 18, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will not share